Breast Cancer
Conditions
Interventions
Group 1:pyrrolidine combined with chemotherapy, endocrinotherapy, and radiotherapy, etc. Group 2: pyrrolidine along with trastuzumab combined with chemotherapy, endocrinotherapy , and radiotherapy, et
Sponsors
The Affiliated Cancer Hospital of Guizhou Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically diagnosed advanced breast cancer, including inoperable locally advanced breast cancer, newly diagnosed stage IV (staging based on AJCC 8th edition) or recurrent/metastatic breast cancer; 2. Histopathologically confirmed HER-2 positive: immunohistochemical (IHC) test results are 3+ or in situ hybridization (ISH) results are HER2 gene amplification (HER2/CEP17 >= 2.0 or average HER2 copy number/cell >= 6); 3. At least one measurable lesion (RECIST1.1); 4. The researcher believes that it can benefit; 5. Voluntarily participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Suffering from mental illness or psychotropic substance abuse and cannot cooperate; 2. Pregnant or lactating patients; 3. Those who are deemed unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival;Adverse reaction;CNS (central nervous system) metastasis; | — |
Countries
China
Contacts
Public ContactRan Li
The Affiliated Cancer Hospital of Guizhou Medical University
Outcome results
None listed